BMRN in the 13F filings
Biomarin Pharmaceutical Inc · CUSIP 09061G101
- Quarter end
- 30 Sep 2025
- the date the book describes
- Filed
- 15 Dec 2025
- latest of these filings; the earliest 13 Nov 2025
- Managers listing it
- 16
- at least, of 95 tracked, among listed positions
- Comparable managers
- 95
- filed both Q2 2025 and Q3 2025; 14 listed it in both
- Shares listed
- 41,963,575
- combined, among listed positions
- Reported value
- $2.3bn
- combined, at the quarter end
Among the 95 comparable managers: 10 buyers (opened or added shares) and 5 sellers (trimmed or exited), at least, among listed positions. Their net change in shares is not known from listed positions, because at least one of them lists it in only one of the two quarters.
Managers listing BMRN in Q3 2025
16 of 16 holders
Largest increases and reductions, by shares
Increases
- Capital Research Global Investorsexisting position · 2,537,596 shares now+2,145,717
- AQR Capital Management LLCexisting position · 5,932,109 shares now+351,536
- Schonfeld Strategic Advisors LLCexisting position · 475,398 shares now+244,243
- Hudson Bay Capital Management LPexisting position · 693,894 shares now+167,474
- Bridgewater Associates LPexisting position · 375,683 shares now+147,937
Reductions
- Viking Global Investors LPexisting position · 8,322,179 shares now-3,966,432
- Dodge & Coxexisting position · 14,686,801 shares now-421,509
- Voloridge Investment Management LLCexisting position · 601,046 shares now-421,263
- Squarepoint Ops LLCexisting position · 1,388,524 shares now-283,923
- Millennium Management LLCexisting position · 2,627,210 shares now-207,145
New positions and exits
New (0)
No new position among listed positions.
Exited (0)
No exit shown by a manager’s own filing.
Ownership over time
Tracked managers listing it, at least.
| Quarter | Holders | Reported value | Buyers | Sellers |
|---|---|---|---|---|
| Q2 2013 | 14 | $2.3bn | n.a. | n.a. |
| Q3 2013 | 14 | $2.8bn | n.a. | n.a. |
| Q4 2013 | 11 | $2.5bn | n.a. | n.a. |
| Q1 2014 | 8 | $2.1bn | n.a. | n.a. |
| Q2 2014 | 9 | $1.9bn | n.a. | n.a. |
| Q3 2014 | 8 | $2.5bn | n.a. | n.a. |
| Q4 2014 | 12 | $3.3bn | n.a. | n.a. |
| Q1 2015 | 15 | $5.4bn | n.a. | n.a. |
| Q2 2015 | 14 | $6.3bn | n.a. | n.a. |
| Q3 2015 | 20 | $5.1bn | n.a. | n.a. |
| Q4 2015 | 14 | $4.8bn | n.a. | n.a. |
| Q1 2016 | 10 | $3.4bn | n.a. | n.a. |
| Q2 2016 | 11 | $2.7bn | n.a. | n.a. |
| Q3 2016 | 17 | $3.7bn | n.a. | n.a. |
| Q4 2016 | 13 | $3.0bn | n.a. | n.a. |
| Q1 2017 | 11 | $3.2bn | n.a. | n.a. |
| Q2 2017 | 14 | $3.2bn | n.a. | n.a. |
| Q3 2017 | 16 | $3.9bn | n.a. | n.a. |
| Q4 2017 | 16 | $3.8bn | n.a. | n.a. |
| Q1 2018 | 17 | $3.3bn | n.a. | n.a. |
| Q2 2018 | 14 | $3.6bn | n.a. | n.a. |
| Q3 2018 | 14 | $3.6bn | n.a. | n.a. |
| Q4 2018 | 13 | $3.0bn | n.a. | n.a. |
| Q1 2019 | 15 | $3.1bn | n.a. | n.a. |
| Q2 2019 | 19 | $3.0bn | n.a. | n.a. |
| Q3 2019 | 13 | $2.1bn | n.a. | n.a. |
| Q4 2019 | 15 | $3.0bn | n.a. | n.a. |
| Q1 2020 | 14 | $2.5bn | n.a. | n.a. |
| Q2 2020 | 11 | $3.6bn | n.a. | n.a. |
| Q3 2020 | 12 | $3.0bn | n.a. | n.a. |
| Q4 2020 | 12 | $3.7bn | n.a. | n.a. |
| Q1 2021 | 10 | $3.1bn | n.a. | n.a. |
| Q2 2021 | 11 | $3.4bn | n.a. | n.a. |
| Q3 2021 | 14 | $3.0bn | n.a. | n.a. |
| Q4 2021 | 14 | $3.4bn | n.a. | n.a. |
| Q1 2022 | 19 | $3.0bn | n.a. | n.a. |
| Q2 2022 | 21 | $2.9bn | n.a. | n.a. |
| Q3 2022 | 25 | $3.1bn | n.a. | n.a. |
| Q4 2022 | 26 | $4.0bn | n.a. | n.a. |
| Q1 2023 | 20 | $3.3bn | n.a. | n.a. |
| Q2 2023 | 18 | $2.9bn | n.a. | n.a. |
| Q3 2023 | 18 | $2.9bn | n.a. | n.a. |
| Q4 2023 | 22 | $4.1bn | 14 | 8 |
| Q1 2024 | 19 | $3.6bn | 16 | 4 |
| Q2 2024 | 16 | $3.3bn | 10 | 6 |
| Q3 2024 | 16 | $3.0bn | 9 | 8 |
| Q4 2024 | 14 | $3.0bn | 11 | 2 |
| Q1 2025 | 16 | $3.3bn | 12 | 3 |
| Q2 2025 | 16 | $2.5bn | 12 | 5 |
| Q3 2025 | 16 | $2.3bn | 10 | 5 |
| Q4 2025 | 21 | $2.4bn | 24 | 19 |
| Q1 2026 | 15 | $2.6bn | 14 | 26 |
| Q2 2026 | 12 | $2.2bn | 13 | 22 |
Compare with…
Holders over time, buyers and sellers, and the managers holding both, side by side for up to four stocks.
BMRN and LLY →BMRN and JNJ →BMRN and VRTX →Choose a stock to compare with BMRN →
How much of the picture this is
A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. It shows no shorts, cash, bonds or performance, and it is never today’s portfolio. Large books are listed to their largest positions, so a manager missing from this table may still hold a small position below that line. These are 95 tracked managers, not the institutional market.
Which funds own BMRN, latest filings →Back to the 13F Explorer →